Myotonic Dystrophy Epidemiology Forecast 2024-2032

Myotonic Dystrophy Epidemiology Forecast Report Coverage

Expert Market Research's “Myotonic Dystrophy Epidemiology Forecast Report 2024-2032” offers comprehensive information on the prevalence and demographics of myotonic dystrophy. It projects the future incidence and prevalence rates of myotonic dystrophy across various populations. The study covers age, gender, and type as major determinants of the myotonic dystrophy-affected population. The report highlights patterns in the prevalence of myotonic dystrophy over time and projects future trends based on multiple variables.

Myotonic Dystrophy Disease Overview

Myotonic dystrophy is a genetic disorder that affects various parts of the body, including the muscles, eyes, heart, and brain. It is considered the most common form of muscular dystrophy that starts in adulthood and is characterized by progressive muscle wasting and weakness. There are two main types of myotonic dystrophy: type 1 (DM1) and type 2 (DM2). DM1 causes muscle weakness in distal muscles whereas DM2 affects proximal muscles.

Myotonic Dystrophy: Treatment Overview

Treatment for myotonic dystrophy focuses on managing symptoms, improving quality of life, and preventing complications. Sodium channel blockers like mexiletine are commonly prescribed for muscle-related symptoms. Endocrine disorders linked with myotonic dystrophy (diabetes, hypothyroidism, etc.) are treated with hormonal therapies. Emerging treatments such as gene therapy, antisense oligonucleotides (ASOs), and CRISPR gene editing, are increasingly being explored to effectively address the root causes of the disease.

Epidemiology

The myotonic dystrophy epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for myotonic dystrophy by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for myotonic dystrophy and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• As per a systematic review and meta-analysis published in Neuroepidemiology (2022), the global prevalence of myotonic dystrophy varies widely, ranging from 0.37 to 36.29 cases per 100,000.
• The pooled estimate of the prevalence is 9.99 cases of myotonic dystrophy per 100,000, with DM1 at 9.27 cases (range: 0.37–36.29) and DM2 at 2.29 cases (range: 0.00–24.00) per 100,000, according to Liao, Qiao et al (2022).
• Inherited in an autosomal dominant pattern, myotonic dystrophy affects around 1 in 8000 individuals worldwide. Further, it is reported that DM is the most common muscular dystrophy among people of European ancestry.
• The Myotonic Dystrophy Foundation states that 1 in 2,100 individuals or 3.6 million people suffer from myotonic dystrophy.

Country-wise Myotonic Dystrophy Epidemiology

The myotonic dystrophy epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of myotonic dystrophy differs between countries due to factors such as genetic predisposition, population-specific mutations, and differences in diagnostic practices and awareness. The prevalence of the two types of myotonic dystrophy is found to differ across geographic and ethnic populations. While type 1 is generally more common in most populations, recent studies indicate that type 2 myotonic dystrophy may occur as frequently as type 1 in regions such as Germany and Finland.

Country Specific Stats:

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of myotonic dystrophy based on several factors.
• Myotonic Dystrophy Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of myotonic dystrophy are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of myotonic dystrophy epidemiology in the 8 major markets?
• What will be the total number of patients with myotonic dystrophy across the 8 major markets during the forecast period?
• What was the country-wise prevalence of myotonic dystrophy in the 8 major markets in the historical period?
• Which country will have the highest number of myotonic dystrophy patients during the forecast period of 2024-2032?
• Which key factors would influence the shift in the patient population of myotonic dystrophy during the forecast period of 2024-2032?
• What are the currently available treatments for myotonic dystrophy?
• What are the disease risks, signs, symptoms, and unmet needs of myotonic dystrophy?

Related Reports

Global Duchenne Muscular Dystrophy (DMD) Treatment Market